# Mirum Pharmaceuticals, Inc. (MIRM) FY2026 YTD Q2 P&L / Income Statement

- Company: Mirum Pharmaceuticals, Inc. (MIRM)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001759425-26-000045
- Page: https://plicit.ai/financials/mirm/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/mirm-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Product sales, net**: 336,125,000 US dollars
- **Total operating expenses**: 1,168,127,000 US dollars
- **Loss from operations**: negative 832,002,000 US dollars
- **Other income (expense), net (calculated)**: negative 23,216,000 US dollars
- **Net loss before provision for income taxes**: negative 855,218,000 US dollars
- **Provision for income taxes**: 2,164,000 US dollars
- **Net loss**: negative 857,382,000 US dollars
- **Livmarli**: 242,525,000 US dollars
- **Bile Acid Medicines**: 93,600,000 US dollars
- **Total operating expenses**: 1,168,127,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.